$610,000.00 in Sales Expected for Arrowhead Pharmaceuticals Inc (ARWR) This Quarter

Share on StockTwits

Wall Street analysts expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report sales of $610,000.00 for the current quarter, Zacks reports. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $700,000.00. Arrowhead Pharmaceuticals reported sales of $9.34 million in the same quarter last year, which indicates a negative year over year growth rate of 93.5%. The company is expected to report its next quarterly earnings report on Thursday, August 2nd.

On average, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $5.86 million for the current year, with estimates ranging from $5.16 million to $8.00 million. For the next financial year, analysts expect that the business will post sales of $54.03 million per share, with estimates ranging from $800,000.00 to $164.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative return on equity of 50.05% and a negative net margin of 199.55%. The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $4.04 million.

A number of brokerages recently issued reports on ARWR. S&P Equity Research lowered their price objective on Arrowhead Pharmaceuticals from $13.76 to $11.68 in a research report on Monday, June 18th. Cantor Fitzgerald reiterated a “buy” rating and issued a $13.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, June 18th. BidaskClub upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. Piper Jaffray Companies increased their price objective on Arrowhead Pharmaceuticals to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 8th. Finally, ValuEngine upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. Arrowhead Pharmaceuticals has an average rating of “Buy” and a consensus price target of $9.45.

In related news, Director Douglas B. Given sold 25,000 shares of the stock in a transaction on Tuesday, April 24th. The stock was sold at an average price of $6.63, for a total value of $165,750.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kenneth Allen Myszkowski sold 20,000 shares of the stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $14.01, for a total value of $280,200.00. Following the completion of the transaction, the chief financial officer now directly owns 330,815 shares in the company, valued at approximately $4,634,718.15. The disclosure for this sale can be found here. In the last three months, insiders sold 59,000 shares of company stock worth $599,950. 4.60% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allianz Asset Management GmbH increased its stake in Arrowhead Pharmaceuticals by 2.2% in the fourth quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock valued at $1,701,000 after acquiring an additional 9,985 shares during the last quarter. Uniplan Investment Counsel Inc. increased its stake in Arrowhead Pharmaceuticals by 1.5% in the first quarter. Uniplan Investment Counsel Inc. now owns 724,228 shares of the biotechnology company’s stock valued at $5,221,000 after acquiring an additional 10,506 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new position in shares of Arrowhead Pharmaceuticals during the first quarter valued at about $100,000. Schwab Charles Investment Management Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 8.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock valued at $686,000 after buying an additional 15,132 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Arrowhead Pharmaceuticals during the first quarter valued at about $139,000. 46.31% of the stock is currently owned by institutional investors and hedge funds.

Shares of ARWR stock traded down $0.16 on Friday, reaching $13.31. The company’s stock had a trading volume of 159,470 shares, compared to its average volume of 2,432,364. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.16 and a current ratio of 10.16. Arrowhead Pharmaceuticals has a 12-month low of $1.48 and a 12-month high of $14.24. The company has a market capitalization of $1.16 billion, a PE ratio of -28.32 and a beta of 2.57.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply